Molecular Classification of HCC

Chairs: Jessica Zucman-Rossi, MD, PhD (France) and Xin Wei Wang, PhD (USA)

  • Non-Tumoral Tissue Signatures in the Molecular Classification
    Yujin Hoshida, MD, PhD (USA)

    There is still a room to improve prognostic prediction for better clinical management of liver cirrhosis and hepatocellular carcinoma (HCC). Studies have revealed that genomic profile of diseased liver is a source of molecular information predictive of variety of clinical outcomes such as intrahepatic tumour metastasis, multi-centric HCC development, cirrhosis progression, and death. It is also known that the prognostic information harbored in diseased liver is independent of HCC tumour and complementary to each other. Integration of these different types of prognostic information will improve precision of prognostic prediction and enable more personalised patient management. For example, molecular biomarkers of HCC risk will guide HCC surveillance as well as follow-up after curative surgery or ablation of primary HCC tumours. In addition, such information may provide clues to treat and/or prevent molecular drivers of poor prognosis and facilitate development of companion biomarkers.